PL3864017T3 - 2,6-dimetylo-n-((pirydyn-4-ylo)metylo)imidazo[1,2-b]pirydazyno-8-amina i pochodne 2,5-dimetylo-n-[(pirydyn-4-ylo)metylo]pirazolo[1,5-a]pirymidyno-7-aminy do leczenia zakażeń wirusowych - Google Patents

2,6-dimetylo-n-((pirydyn-4-ylo)metylo)imidazo[1,2-b]pirydazyno-8-amina i pochodne 2,5-dimetylo-n-[(pirydyn-4-ylo)metylo]pirazolo[1,5-a]pirymidyno-7-aminy do leczenia zakażeń wirusowych

Info

Publication number
PL3864017T3
PL3864017T3 PL19759312.2T PL19759312T PL3864017T3 PL 3864017 T3 PL3864017 T3 PL 3864017T3 PL 19759312 T PL19759312 T PL 19759312T PL 3864017 T3 PL3864017 T3 PL 3864017T3
Authority
PL
Poland
Prior art keywords
pyridin
dimethyl
methyl
amine
pyridazin
Prior art date
Application number
PL19759312.2T
Other languages
English (en)
Inventor
Jacob Westman
Original Assignee
Curovir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curovir Ab filed Critical Curovir Ab
Publication of PL3864017T3 publication Critical patent/PL3864017T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL19759312.2T 2018-10-10 2019-08-20 2,6-dimetylo-n-((pirydyn-4-ylo)metylo)imidazo[1,2-b]pirydazyno-8-amina i pochodne 2,5-dimetylo-n-[(pirydyn-4-ylo)metylo]pirazolo[1,5-a]pirymidyno-7-aminy do leczenia zakażeń wirusowych PL3864017T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18199486 2018-10-10
PCT/EP2019/072220 WO2020074159A1 (en) 2018-10-10 2019-08-20 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections

Publications (1)

Publication Number Publication Date
PL3864017T3 true PL3864017T3 (pl) 2024-02-19

Family

ID=63832264

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19759312.2T PL3864017T3 (pl) 2018-10-10 2019-08-20 2,6-dimetylo-n-((pirydyn-4-ylo)metylo)imidazo[1,2-b]pirydazyno-8-amina i pochodne 2,5-dimetylo-n-[(pirydyn-4-ylo)metylo]pirazolo[1,5-a]pirymidyno-7-aminy do leczenia zakażeń wirusowych

Country Status (16)

Country Link
US (1) US12319696B2 (pl)
EP (1) EP3864017B1 (pl)
JP (1) JP7397072B2 (pl)
KR (1) KR102821765B1 (pl)
CN (1) CN112969703B (pl)
AU (1) AU2019359166B2 (pl)
BR (1) BR112021006388A2 (pl)
CA (1) CA3115128A1 (pl)
ES (1) ES2960698T3 (pl)
IL (1) IL281956B2 (pl)
MX (1) MX2021003915A (pl)
NZ (1) NZ775649A (pl)
PL (1) PL3864017T3 (pl)
SG (1) SG11202103496VA (pl)
WO (1) WO2020074159A1 (pl)
ZA (1) ZA202102974B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4028131B1 (en) 2019-08-20 2023-11-22 Curovir Ab Heteroaromatic compounds useful in therapy
WO2024184442A1 (en) 2023-03-09 2024-09-12 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
JP6509238B2 (ja) * 2014-01-22 2019-05-08 キュロヴィル・アクチボラグ 治療に有用なピラゾロ［１，５−ａ］ピリミジン−７−アミン誘導体
WO2016091774A1 (en) * 2014-12-08 2016-06-16 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
AU2016284638B2 (en) 2015-06-24 2020-01-23 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
AU2018248581B2 (en) 2017-04-05 2022-05-26 Curovir Ab Heteroaromatic compounds useful in therapy

Also Published As

Publication number Publication date
CN112969703B (zh) 2024-11-26
CN112969703A (zh) 2021-06-15
SG11202103496VA (en) 2021-05-28
IL281956A (en) 2021-05-31
ZA202102974B (en) 2023-10-25
AU2019359166B2 (en) 2024-07-11
MX2021003915A (es) 2021-06-04
KR102821765B1 (ko) 2025-06-16
ES2960698T3 (es) 2024-03-06
EP3864017A1 (en) 2021-08-18
KR20210074312A (ko) 2021-06-21
EP3864017C0 (en) 2023-07-26
AU2019359166A1 (en) 2021-05-27
JP2022504082A (ja) 2022-01-13
WO2020074159A1 (en) 2020-04-16
JP7397072B2 (ja) 2023-12-12
IL281956B1 (en) 2024-03-01
EP3864017B1 (en) 2023-07-26
CA3115128A1 (en) 2020-04-16
US20210340147A1 (en) 2021-11-04
NZ775649A (en) 2026-02-27
US12319696B2 (en) 2025-06-03
BR112021006388A2 (pt) 2021-07-06
IL281956B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
IL260020B (en) 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and respectively (1h- indazol-3-yl) derivatives as cGMP activators for the treatment of cardiovascular diseases
EP3976607A4 (en) PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE SUBSTITUTED DERIVATIVES AS PROTEIN KINASE INHIBITORS
PL3458456T3 (pl) Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo [1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karbokysamidu
PL3555097T3 (pl) Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
ZA201904236B (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
PL3500571T3 (pl) Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
IL281956A (en) History of 6,2-dimethyl-N-(pyridin-4-yl)methyl)imidazo[2,1-B]pyridazin-8-amine and 5,2-dimethyl-N-[(pyridin-4-yl)methyl] Pyrazolo[5,1-A]pyrimidine-7-amine for the treatment of viral infections
DK4259632T3 (da) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid og n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid-derivater som irak4-hæmmere til behandling af astma
HK40130482A (zh) 制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法
HK40130483A (zh) 制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose
HK1238643A1 (en) Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
MX2016007494A (es) Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina.